![Mike Casia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Mike Casia
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Director/Miembro de la Junta | - | - |
Organon Canada, Inc. | Director Ejecutivo | - | - |
Presidente | - | - |
Historial de carrera de Mike Casia
Estadísticas
Internacional
Canadá | 3 |
Operativa
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Chairman | 1 |
Sectorial
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Commercial Services |
Organon Canada, Inc. |
- Bolsa de valores
- Insiders
- Mike Casia
- Experiencia